Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable 1.83 2.02 2.22 2.77 2.82
Accrued payroll and related costs 1.87 1.70 1.73 2.71 2.33
Accrued clinical expenses 0.88 1.01 1.16 1.65 0.96
Accrued sales-related costs 2.36 2.17 1.86 2.47 1.68
Other accrued expenses and liabilities 2.02 2.22 3.92 2.75 2.37
Accrued expenses and other current liabilities 7.13% 7.10% 8.68% 9.58% 7.34%
Finance lease liabilities, current portion 0.00 0.00 2.83 0.00 0.00
Deferred revenue 1.39 1.64 1.74 3.37 4.00
Current liabilities 10.35% 10.75% 15.46% 15.72% 14.16%
Long-term debt 5.99 6.78 7.78 11.53 0.00
Finance lease liabilities, excluding current portion 2.18 2.46 0.00 4.18 4.82
Deferred revenue 0.38 0.24 0.29 0.34 4.18
Other noncurrent liabilities 2.58 2.18 2.67 4.00 1.93
Noncurrent liabilities 11.14% 11.67% 10.75% 20.05% 10.93%
Total liabilities 21.48% 22.42% 26.21% 35.76% 25.10%
Preferred Stock, par value $.01 per share; issued and outstanding: none 0.00 0.00 0.00 0.00 0.00
Class A Stock, convertible, par value $.001 per share 0.00 0.00 0.00 0.00 0.00
Common Stock, par value $.001 per share 0.00 0.00 0.00 0.00 0.00
Additional paid-in capital 34.32 34.06 31.80 39.13 29.91
Retained earnings 82.41 79.78 74.58 63.47 49.85
Accumulated other comprehensive income (loss) -0.24 -0.82 -0.10 0.17 0.14
Treasury Stock, at cost -37.97 -35.44 -32.48 -38.53 -5.00
Stockholders’ equity 78.52% 77.58% 73.79% 64.24% 74.90%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc. noncurrent liabilities as a percentage of total liabilities and stockholders’ equity increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2021 to 2022 and from 2022 to 2023.